ICAM-1 Aptamer Composition for Selective Rhinovirus Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for aptamers that selectively bind to cellular membrane glycoproteins, particularly ICAM-1, to prevent human rhinovirus binding and entry into cells, as current treatments lack effective antiviral drugs for common colds caused by rhinoviruses.
Innovation Solution
Development of nucleic acid aptamers with high binding affinity for ICAM-1, designed through SELEX, to inhibit human rhinovirus binding and entry into nasal and throat cells, using truncated oligonucleotides ranging from 30 to 60 nucleotides in length.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aptamers are designed to bind with high affinity to ICAM-1 to prevent rhinovirus binding, then antiviral effectiveness is improved, but the complexity of aptamer selection and validation increases
Solution Approach 1:
The patent segments the complex aptamer development process into distinct phases: initial SELEX screening against ICAM-1, followed by truncated aptamer generation, and finally viral binding inhibition assays. This segmentation allows systematic optimization at each stage, reducing overall complexity while maintaining high antiviral effectiveness.
Solution Approach 2:
The patent performs preliminary action by first selecting aptamers against ICAM-1 (the viral receptor) before testing them for viral binding inhibition. This preliminary selection against the receptor provides a foundation of high-affinity binders, simplifying subsequent viral inhibition assays and improving the likelihood of finding effective antiviral aptamers.
2Ease of operation
If truncated oligonucleotides are used to reduce aptamer length, then ease of administration is improved, but binding affinity may be reduced
Solution Approach 1:
The patent systematically changes the parameter of oligonucleotide length by generating truncated versions of parent aptamers (e.g., reducing from 80-100 nucleotides to 30-60 nucleotides). This parameter change improves ease of administration while the selection process ensures that truncated versions retaining sufficient binding affinity are identified through iterative optimization.
Solution Approach 2:
The patent applies local quality by identifying and preserving the critical binding regions within the truncated oligonucleotides. Through SELEX and structural analysis, the patent ensures that the essential ICAM-1 binding motifs are maintained in the truncated versions, allowing short oligonucleotides to retain high binding affinity while improving administrability.
3Reliability
If aptamers are designed for high specificity to ICAM-1, then viral binding inhibition is improved, but the difficulty of selecting specific aptamers from large libraries increases
Solution Approach 1:
The patent implements feedback mechanisms at multiple stages: SELEX uses iterative binding-assorted amplification with increasing stringency to enrich specific binders, followed by validation against both ICAM-1 and viral particles. This feedback loop ensures that only aptamers with high specificity to ICAM-1 and corresponding viral binding inhibition capability are selected, improving reliability while managing selection difficulty through systematic validation.
Solution Approach 2:
The patent performs preliminary action by first enriching for ICAM-1 binding specificity through SELEX before conducting viral binding inhibition assays. This preliminary specificity selection reduces the search space for subsequent viral inhibition testing, making the overall process more manageable while ensuring high specificity is achieved before final validation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers effectively reduce rhinovirus binding to ICAM-1, potentially mitigating common cold symptoms and preventing infection, offering a novel approach for personal health care compositions.
Implementation Method 1
The molecular recognition of aptamers is based on structure compatibility and intermolecular interactions
Implementation Method 2
including electrostatic forces, van der Waals interactions, hydrogen bonding, and π-π stacking interactions
Implementation Method 3
including electrostatic forces, van der Waals interactions, hydrogen bonding, and π-π stacking interactions
Implementation Method 4
including electrostatic forces, van der Waals interactions, hydrogen bonding, and π-π stacking interactions
Implementation Method 5
aptamers that selectively bind to cellular membrane glycoproteins, including ICAM-1, and that prevent the binding of human rhinoviruses to such glycoproteins
Data Source
AI summary
An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).